ORLANDO, Florida — Use of cannabis is common in patients with multiple sclerosis (MS), especially for the treatment of MS-related spasticity, new research suggests. Findings from a survey conducted ...

December 10, 2009 — Cannabis may be a viable treatment option for some patients with spasticity related to multiple sclerosis (MS), new research suggests. The systematic review, conducted by ...

A new study found smoking cannabis reduced spasticity in MS patients. May 14, 2012— -- Smoking marijuana may reduce certain symptoms in patients with multiple sclerosis, according to a new small ...

(HealthDay News) – Smoking cannabis is associated with a reduction in spasticity for patients with multiple sclerosis (MS), according to a study published online May 14 in CMAJ, the journal of the ...

Investigators assessed a large population of Italian patients with resistant multiple sclerosis spasticity treated with THC:CBD to determine real-life, long-term efficacy outcomes. PHILADELPHIA — Real ...

Dec. 5 -- FRIDAY, Dec. 4 (HealthDay News) -- Cancer patients, glaucoma patients and others can benefit from medical marijuana, and now a new analysis shows that it can help multiple sclerosis (MS) ...

The study, published Monday, found that for 30 MS patients with muscle "spasticity," a few days of marijuana smoking brought some relief. But the big caveat, researchers say, is that it's not clear ...

Arbaclofen extended-release (ER) reduced spasticity in patients with multiple sclerosis and was found to be safe and well-tolerated, according to 2 new abstracts presented at the 33rd Annual Meeting ...

LONDON – GW Pharma plc delivered positive results in a UK Phase III postmarketing study of Sativex, which will provide ballast for the launch of the cannabis-based product as a treatment for ...

Investigators sought to determine the safety and efficacy of twice-daily dosing of arbaclofen ER in patients with spasticity due to multiple sclerosis. SEATTLE – Twice-daily arbaclofen ...

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) said Tuesday that phase 3 RELEASE MSS1 trial, which evaluated nabiximols oromucosal spray on clinical measures of spasticity in individuals with multiple ...